A case of primary pulmonary plasmacytoma presenting as endobronchial mass
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh S.Y. | - |
dc.contributor.author | Ko G.J. | - |
dc.contributor.author | Kim C.H. | - |
dc.contributor.author | Kim Y.H. | - |
dc.contributor.author | Lee S.Y. | - |
dc.contributor.author | Lee S.Y. | - |
dc.contributor.author | Kim J.H. | - |
dc.contributor.author | Shin C. | - |
dc.contributor.author | Shim J.J. | - |
dc.contributor.author | In K.H. | - |
dc.contributor.author | Kang K.H. | - |
dc.contributor.author | Yoo S.H. | - |
dc.date.available | 2020-11-03T17:50:38Z | - |
dc.date.issued | 2004 | - |
dc.identifier.issn | 0378-0066 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/20783 | - |
dc.description.abstract | Extramedullary plasmacytoma(EMP) comprises 5% of all plasma cell neoplasms and commonly occurs in the upper airway or digestive tract. However, it rarely develops in the lungs. We present a case of primary pulmonary plasmacyotma in a 45 year old man, who presented as an endobronchial mass with a pleural effusion, but without evidence of multiple myeloma. The treatment options for EMP include surgery, surgery and radiotherapy, surgery and chemotherapy or chemotherapy alone. Surgery and radiation therapy appeared to be equally effective forms of treatment. The local recurrence rate was reported to be 30%, with 48% progressing to multiple myeloma, and median survival was reported to be 63-101 months. Our patient was initially treated with melphalan and prednisolone. However the disease progressed, and radiotherapy was combined with chemotherapy. In addition, the chemotherapy regimen was also changed to thalidomide and dexamethasone. The patient did not respond to this treatment regimen and finally died. | - |
dc.format.extent | 6 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | Korean National Tuberculosis Association | - |
dc.title | A case of primary pulmonary plasmacytoma presenting as endobronchial mass | - |
dc.type | Article | - |
dc.identifier.doi | 10.4046/trd.2004.56.6.664 | - |
dc.identifier.scopusid | 2-s2.0-4444248792 | - |
dc.identifier.bibliographicCitation | Tuberculosis and Respiratory Diseases, v.56, no.6, pp 664 - 669 | - |
dc.citation.title | Tuberculosis and Respiratory Diseases | - |
dc.citation.volume | 56 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 664 | - |
dc.citation.endPage | 669 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001117220 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | antineoplastic agent | - |
dc.subject.keywordPlus | dexamethasone | - |
dc.subject.keywordPlus | melphalan | - |
dc.subject.keywordPlus | prednisolone | - |
dc.subject.keywordPlus | thalidomide | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | bronchus tumor | - |
dc.subject.keywordPlus | cancer growth | - |
dc.subject.keywordPlus | cancer recurrence | - |
dc.subject.keywordPlus | cancer survival | - |
dc.subject.keywordPlus | case report | - |
dc.subject.keywordPlus | death | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | multiple myeloma | - |
dc.subject.keywordPlus | plasmacytoma | - |
dc.subject.keywordPlus | pleura effusion | - |
dc.subject.keywordPlus | primary pulmonary plasmacytoma | - |
dc.subject.keywordPlus | rare disease | - |
dc.subject.keywordPlus | treatment indication | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordAuthor | Endobronchial mass | - |
dc.subject.keywordAuthor | Extramedullary plasmacytoma | - |
dc.subject.keywordAuthor | Pulmonary plasmacytoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.